Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07095972 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Continuous Glucose Monitoring in Metabolic Surgery

StatusNot Yet Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Start date: Aug 15, 2026 to Sep 20, 2026 Show 6 more changesShow less
    • Primary completion moved earlier from Aug 30, 2027 to Jun 30, 2027
    • Study completion moved earlier from Aug 31, 2027 to Jul 30, 2027
    • Secondary endpoints: details revised at 2 of 2 entries
    • Study description revised
    • Publications: details revised at 4 of 4 entries
    • Eligibility criteria shortened, about 2 words
  2. Start date: Jul 15, 2026 to Aug 15, 2026
    • Primary completion pushed from Apr 30, 2027 to Aug 30, 2027
    • Study completion pushed from May 31, 2027 to Aug 31, 2027
    • Eligibility criteria revised
    v8
  3. Start date: May 15, 2026 to Jul 15, 2026
    • Eligibility criteria revised
    v7
  4. Primary completion pushed from Dec 30, 2026 to Apr 30, 2027
    • Study completion moved earlier from Jun 30, 2027 to May 31, 2027
    • Eligibility criteria revised
    v6
  5. Start date: Apr 1, 2026 to May 15, 2026v5
Show 3 earlier versionsHide 3 earlier versions
  1. Start date: Feb 1, 2026 to Apr 1, 2026v4 Show 6 more changesShow less
    • Primary completion date: Nov 30, 2026 to Dec 30, 2026
    • Study completion date: Dec 31, 2026 to Jun 30, 2027
    • Secondary endpoints: 3 to 2
    • Study description shortened, about 209 words
    • Site contact updated
    • Eligibility criteria shortened, about 2 words
  2. Start date: Sep 1, 2025 to Feb 1, 2026
    • Primary completion date: Jun 30, 2026 to Nov 30, 2026
    • Study completion date: Jul 31, 2026 to Dec 31, 2026
    • Site contact updated
    v3
  3. Eligibility criteria shortened, about 14 words
    • Study description expanded, about 1 word
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
We will recruit 20 severely obese participants at Metamor Institute. Participants with obesity who are eligible for MBS will be randomized to either CGM group or self-monitoring of blood glucose (SMBG) group before the surgery based on a 1:1 ratio. All participants live in Baton Rouge, Louisiana. The surgeon in Metamor will introduce our study to the patients. If the patients are interested, the evaluation process includes verifying basic personal information, assessing health status and medical history, and evaluating specific eligibility criteria relevant to the study. The study coordinator will be discussing informed consent, ensuring participants understand the study's purpose, procedures, and any associated risks or benefits. Participants are encouraged to ask questions, ensuring clarity and comfort with the study. All collected data is documented and securely stored, respecting data privacy protocols. Eligible individuals are informed about the screening visit, while those not suitable are considered for future studies.
Trial Details
NCT Number NCT07095972
Lead Sponsor Pennington Biomedical Research Center
Collaborators: LA CaTS Clinical Research Resources Core
Conditions
(from sponsor)		 Obesity (Disorder)
Related terms Obesity, Obesity, Morbid
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov